Researchers have identified strong evidence linking adiposity to changes in sex steroid hormone levels, with surgical weight loss substantially reducing circulating testosterone and androstenedione. Meanwhile, a new pilot study is comparing robotic-assisted surgery against conventional laparoscopy to treat deep infiltrating endometriosis, focusing on symptom improvement and pain relief for patients.
How Body Fat Alters Sex Steroid Hormones
Surgical weight loss procedures resulted in a significant reduction in circulating testosterone levels, with a standardized mean difference of −0.47 based on ten studies. A systematic review and meta-analysis has clarified the relationship between body fat and hormone regulation, finding that weight loss interventions often lead to measurable changes in hormonal profiles. This finding suggests a probable causal association between fat mass reduction and lowered testosterone, a trend that appears consistent across surgical and lifestyle interventions.
The evidence regarding androstenedione follows a similar pattern, with surgical weight loss interventions showing a significant decrease in circulating levels. However, the data for other hormones is more complex. While lifestyle interventions were linked to a significant decrease in circulating estradiol, results for urinary estrone metabolites were inconsistent. Some studies showed no significant change in 2-OHE1 following four-month interventions, despite significant losses in body fat mass. Evidence regarding DHEAS concentrations following surgical weight loss remained non-significant.
Evaluating Robotic Versus Laparoscopic Endometriosis Surgery
A new single-center, prospective pilot study is currently evaluating the efficacy of robotic surgery compared to conventional laparoscopy. While researchers analyze the systemic impact of body fat on hormones, clinical teams are simultaneously investigating surgical techniques to manage deep infiltrating endometriosis. The trial aims to determine if robotic systems provide superior pain relief for patients with lesions sized at least 1, as classified by the Enzian score.
- Subjective symptom improvement measured via the Visual Analog Scale (VAS) for pain.
- Disease recurrence rates assessed up to 12 months post-surgery.
- Condition-specific quality of life improvements and medication usage.
Tracking Patient Progress During Postoperative Follow-up
Postoperative follow-up visits are scheduled for three and six months, where patients will report their progress through the Patient Global Impression of Change and the Endometriosis Health Profile (EHP-30). The surgical teams are using the da Vinci Surgical System Si for the robotic-assisted group, utilizing up to five ports, while the laparoscopic group uses up to four. To ensure consistent baseline data, participants are required to document their pain levels for at least one calendar month before their operation.